Life Sciences

  • October 21, 2026

    Intuitive Surgical Strikes $450M Deal In Robot Antitrust Suit

    Intuitive Surgical said in its quarterly earnings report Tuesday that it reached a $450 million settlement to resolve a hospital class action alleging it monopolized the market for servicing its da Vinci surgical robots, subject to approval by a California federal judge.

  • October 21, 2026

    Amarin Ends 'Skinny Label' Patent Case Against Hikma

    Amarin Pharma Inc. is dropping its patent suit over Hikma Pharmaceuticals USA Inc.'s generic version of a heart drug that uses a so-called skinny label, months after the U.S. Supreme Court shut the case down.

  • October 21, 2026

    Squire Patton Lands Akerman's Public Finance Co-Leader

    Squire Patton Boggs LLP announced Wednesday that it has added the co-chair of Akerman LLP's public finance group to bolster its capacity to handle public finance, healthcare finance and other matters.

  • October 21, 2026

    High Court Lets Block On Prison Gender Care Ban Stand

    The U.S. Supreme Court on Wednesday allowed federal prisons to continue to offer gender transition medical services to incarcerated people.

  • October 20, 2026

    Medical Device Co. Beats Investors' Alleged Demand Drop Suit

    A New York federal judge has dismissed a proposed shareholder class action alleging medical device maker Integer Holdings Corp. hid plummeting demand for cardiac devices and misled investors about its overall growth, concluding that the allegations do not suggest its disclosures in 2024 and 2025 were untrue or deceptive.

  • October 20, 2026

    Squires Grants 10 Patent Review Bids, Rejects 2 Others

    In his latest round of decisions, U.S. Patent and Trademark Office Director John Squires has granted 10 petitions seeking review of patents and denied two others, both on discretionary grounds.

  • October 20, 2026

    Genentech, Novartis Sue Amneal Over Bid To Sell Xolair Copy

    Genentech Inc. and Novartis Pharmaceuticals Corp. have filed a patent infringement suit in Delaware federal court, claiming Kashiv BioSciences' bid to sell a biosimilar copy of their prescription allergy drug Xolair amounts to patent infringement.

  • October 20, 2026

    Zymergen Investors Win Final OK Of $125M IPO Deal

    Investors in the now-defunct biotechnology company Zymergen received final approval of their $125 million deal ending claims that the company misled shareholders ahead of its initial public offering, while plaintiffs' attorneys also had their fee request approved. 

  • October 20, 2026

    2nd Circ. Won't Block Connecticut Drug Price Cap

    A Second Circuit panel affirmed a lower court's decision Tuesday, refusing to block Connecticut from enforcing a cap on generic and off-patent drug prices while a trade association for drug wholesalers challenges the statute.

  • October 20, 2026

    Omnicare Seeks 3rd Change To Ch. 11 Loan Ahead Of Maturity

    Pharmacy service provider Omnicare has asked a Texas bankruptcy judge for permission to make a third set of tweaks to its $110 million debtor-in-possession financing agreement, including when the loan comes due, saying the debtor won't be able to consummate its sale to spin off from parent company CVS before the current maturity date.

  • October 20, 2026

    8th Circ. Panel Doubts Investors' Medtronic Insulin Pump Suit

    The Eighth Circuit appeared skeptical Tuesday of investors' bid to revive allegations that medical device company Medtronic failed to properly communicate problems with an insulin pump device it manufactured and was ultimately recalled, with judges questioning arguments that certain interactions between the company and regulators weren't properly disclosed.

  • October 20, 2026

    Polsinelli Seeks Sanctions For 'Knowingly False' IP Suit

    Law firm Polsinelli PC has asked a Tennessee federal judge to sanction a medical device company for advancing what it says were "knowingly false and materially incomplete" positions in a suit accusing the firm of pursuing bad faith patent infringement claims on behalf of a client.

  • October 20, 2026

    CMA Seeks Views On Intersurgical's Teleflex Deal

    Britain's antitrust regulator invited comments Tuesday on whether local medical device maker Intersurgical's proposed $530 million acquisition of two businesses could harm competition in U.K. markets.

  • October 20, 2026

    Freshfields Hires Gibson Dunn Life Sciences Lawyer In DC

    Freshfields LLP has hired a former Gibson Dunn & Crutcher LLP lawyer who focuses his practice on identifying, assessing and mitigating risks associated with U.S. Food and Drug Administration oversight, the firm recently announced.

  • October 19, 2026

    23andMe Successor Co. Inks $6M Data Breach Deal With Calif.

    California and 23andMe's corporate successor have reached a $6 million settlement that, if approved, would resolve the state's allegations that the genetic testing company failed to protect customers' sensitive information in a 2023 data breach, as well as the state's objection to 23andMe's sale of genetic data during bankruptcy proceedings.

  • October 19, 2026

    5 Firms Build Migraine-Focused TriGemX's $600M SPAC Deal

    Biotechnology company TriGemX Bio on Monday unveiled plans to go public by merging with special purpose acquisition company TCGX Acquisition Corp. in a deal built by five law firms that creates a combined company with a $600 million post-transaction equity value.

  • October 19, 2026

    5th Circ. Unwinds Cassava Class Over 'Meme Stock' Claims

    The Fifth Circuit has overturned the class status of investors accusing Cassava Sciences Inc. of making misleading statements about clinical trial results for a potential Alzheimer's drug, saying that a lower court judge did not properly consider the company's arguments that its stock price was impacted by the "meme stock" craze.

  • October 19, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week blocked Cloudflare Inc. from completing a restructuring meant to preserve its founders' voting control, while Tower Semiconductor Ltd. accused Intel Corp. of backing out of a semiconductor manufacturing agreement and social media company Triller Group Inc. challenged its removal from Nasdaq.

  • October 19, 2026

    Prior 5th Amendment Pleadings Complicate Mylan Testimony

    Mylan can use deposition testimony from one current and one former executive in next year's price-fixing trial, a Connecticut federal judge ruled Friday, but state attorneys general can bring up the company "pulling the strings" in the witnesses' decision to testify after originally invoking the Fifth Amendment.

  • October 19, 2026

    DOJ Appeals New Trial Order In Ex-NFL Player's Fraud Case

    The U.S. Department of Justice said it's asking the Fifth Circuit to review a Texas federal judge's decision to grant a new trial for a former NFL player convicted in a $328 million Medicare billing scheme.

  • October 19, 2026

    A&O Shearman, Cooley Guide Merck's $1.3B UK Biotech Deal

    Germany's Merck said Monday it has agreed to acquire U.K. biotechnology company Silence Therapeutics PLC at a $1.3 billion equity value, with Allen Overy Shearman Sterling advising Merck and Cooley LLP representing Silence Therapeutics.

  • October 19, 2026

    Full Fed. Circ. Won't Revive Insulet's $59M Trade Secrets Win

    The Federal Circuit will not reinstate a jury's $59.4 million trade secret theft verdict against EOFlow Co. Ltd., rejecting insulin product developer Insulet Corp.'s request for rehearing of a panel decision overturning the award.

  • October 16, 2026

    2nd Circ. Denies Rehearing In Tylenol Autism Suits

    The Second Circuit on Friday denied a bid by Tylenol maker Kenvue and several retailers to reconsider its ruling that a district court improperly excluded expert testimony for plaintiffs who claim prenatal exposure to the over-the-counter pain reliever causes autism and ADHD.

  • October 16, 2026

    Suing The Trump Admin Can Have Massive Impact, Attys Say

    Lawyers representing clients against the federal government spoke Friday about the challenges and rewards of such litigation in the Trump era, with plaintiff-side powerhouse Elizabeth Cabraser pointing to the potential for massive impact, including one case in which she successfully got more than a billion dollars in grant funding reinstated.

  • October 16, 2026

    Device Co. Accused Of Shorting Co-Founder's Payments

    The co-founder of a company that sells medical devices told a Colorado state court Thursday that the company lowered the percentage he is owed of $7.7 million in outstanding receivables from a client without approval.

Expert Analysis

  • 6th Circ. Spotlights Cannabis Contract Enforceability Risks

    Author Photo

    The Sixth Circuit's recent reversal of a $31.8 million jury verdict against a subsidiary of cannabis giant Curaleaf highlights that state licenses do not necessarily provide the legal foundation needed to enforce contracts in federal court, which is a pattern that appears across many sectors, say attorneys at ArentFox Schiff.

  • Where DOJ's Fraud Directive May Actually Affect Enforcement

    Author Photo

    The U.S. Department of Justice’s recent directive outlining corporate fraud enforcement priorities is mostly a management document instead of a policy, but one part may actually undermine the directive's goals by leading to worse outcomes for organizational defendants and less corporate self-disclosure, says Zachary Warren at Williams & Connolly.

  • Why Vaccine Court Inoculates Drugmakers Against Litigation

    Author Photo

    Most claimants alleging injuries from routine childhood vaccines must complete an administrative compensation proceeding before they can sue in civil court — and recent legislative efforts aimed at weakening vaccine manufacturers' legal protections do not account for the important reasons the existing framework was put in place, say attorneys at Goldman Ismail.

  • What Lawyers Should Know Before Accepting Crypto Payment

    Author Photo

    As clients increasingly request to pay legal fees, retainers and escrow funds using cryptocurrency, lawyers should consider how only a handful of state bar authorities have addressed the issue with varying ethics opinions, as well as the related questions that no authority has yet answered, says attorney Felix Shipkevich.

  • What To Know As State 'Neural Data' Privacy Laws Emerge

    Author Photo

    Attorneys at Goodwin discuss new state laws aimed at regulating consumer data generated from nervous system activity, explain why neurotechnology is attracting state and federal legislators’ attention, and highlight the compliance obligations that industry players should address now.

  • Data Sale In Spirit Bankruptcy Raises Novel Privacy Risks

    Author Photo

    Spirit Airlines' planned sale of deidentified business data to Google for artificial intelligence training exposes gaps in the Bankruptcy Code's privacy guardrails, particularly for employee information, say attorneys at Patterson Belknap.

  • IDScan Data Breach Puts Spotlight On Vendor Oversight

    Author Photo

    A recently reported breach that exposed millions of identification documents held by IDScan.net highlights the liability risks for businesses that contract with third-party identity processors, and emphasizes the importance of auditing vendors' data retention practices, say attorneys at Tucker Ellis.

  • Series

    Mentalism Makes Me A Better Lawyer

    Author Photo

    Convincing strangers I can read their minds may seem like an unusual second career for a legal practitioner, but both disciplines share several important requirements, including trust and preparation, says Warren Biro at Manatt.

  • Why And How To Build A Neurodiversity-Informed Practice

    Author Photo

    By better understanding neurodiversity and implementing simple accommodations for clients with autism, ADHD or learning differences, attorneys can build stronger relationships with those who may otherwise struggle to obtain and benefit from legal services, while developing good habits that will benefit everyone they represent, says Ting Cheung at Sanford Heisler.

  • Opinion

    PTAB Panels Should Revamp Their IPR Merits Decisions

    Author Photo

    In light of U.S. Patent and Trademark Office Director John Squires' recent announcement about returning merits institution determinations to the Patent Trial and Appeal Board, the implementing framework should strengthen PTAB panels' responsibility for the benefit of both petitioners and patent owners, says Brandon Theiss at AddyHart.

  • Patent Eligibility Bulletin: Claim Solutions, Not Results

    Author Photo

    In the third quarter of the year, two Federal Circuit decisions illustrated that claims sharing the same disclosure can fall on opposite sides of the patent eligibility line, depending on the specific nuances of tech patents' claims, says Reilley Keane at Banner Witcoff.

  • Abbott FCA Deal Shows Enforcement Adequacy Quandaries

    Author Photo

    Abbott Laboratories’ recent False Claims Act resolution illustrates several tricky questions that both prosecutors and defense counsel must address when weighing whether a civil enforcement action alone adequately addresses allegedly wrongful conduct, says James Koukios at MoFo.

  • New DNA Screening Standard Has No Clear Playbook

    Author Photo

    Although the government has not yet released promised guidance intended to support its new standards for screening mail-order DNA, companies should not read this as a reprieve from the Oct. 13 compliance deadline because the delay shifts enforcement risk to statutes that need no new authority, including false statements, the False Claims Act and fraud, says Ashwin Ram at Buchalter.

  • Series

    Mich. Banking Brief: All The Notable Legal Updates In Q3

    Author Photo

    We are at an inflection point for Michigan financial services law, with a state Supreme Court decision recently overruling more than 25 years of precedent on the Michigan Consumer Protection Act, and pending legislation that could significantly shift the regulatory landscape, say attorneys and advisers at Dykema.

  • Testing AI's Promise For Large-Scale Document Review

    Author Photo

    Our document-review comparison of attorneys' responsiveness and issue coding decisions versus predictions generated by artificial intelligence across 1,600 documents suggests that these tools can offer a reasonable and reliable basis for improved discovery workflows, provided lawyers understand where guardrails are needed, say attorneys at Redgrave.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here